scholarly journals Effect of oral intake of a Lactococcus lactis strain on skin properties of women ^|^mdash;a Pilot Study^|^mdash;

2012 ◽  
Vol 83 (3) ◽  
pp. 307-313 ◽  
Author(s):  
Hiromi KIMOTO-NIRA ◽  
Reiji AOKI ◽  
Keisuke SASAKI ◽  
Chise SUZUKI ◽  
Koko MIZUMACHI
Keyword(s):  
Pilot Study ◽  
Lactococcus Lactis ◽  
Oral Intake ◽  
Lactis Strain

scholarly journals Lactococcus lactis Strain Plasma Intake Suppresses the Incidence of Dengue Fever-like Symptoms in Healthy Malaysians: A Randomized, Double-Blind, Placebo-Controlled Trial

Nutrients ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 4507
Author(s):  
Chee-Sieng Khor ◽  
Ryohei Tsuji ◽  
Hai-Yen Lee ◽  
Siti-Sarah Nor’e ◽  
Norhidayu Sahimin ◽  
...  
Keyword(s):  
Dengue Fever ◽  
Lactococcus Lactis ◽  
Clinical Symptoms ◽  
Controlled Trial ◽  
Serum Antibody ◽  
Oral Intake ◽  
Double Blind ◽  
Lactis Strain ◽  
Antigen Tests ◽  
Study Sites

Dengue fever (DF) is a mosquito-borne disease still with no effective treatment or vaccine available. A randomized, placebo-controlled, double-blinded, parallel-group trial was undertaken to evaluate the efficacy of oral intake of Lactococcus lactis strain plasma (LC-Plasma) on the presentation and severity of DF-like symptoms among healthy volunteers. Study participants (320) were assigned into two groups, and consumed either placebo or LC-Plasma tablets (approximately 100 billion cells/day) for 8 weeks. The clinical symptoms of DF were self-recorded through questionnaires, and exposure to DENV was determined by serum antibody and/or DENV antigen tests. No significant differences between groups were observed for exposure to DENV, or the symptomatic ratio. Results obtained showed that participants from the LC-Plasma group reported a significant reduction in the cumulative incidence days of DF-like symptoms, which include fever (p < 0.001), muscle pain (p < 0.005), joint pain (p < 0.001), and pain behind the eyes (p < 0.001), compared to that of the placebo group. Subgroup analysis revealed a significantly (p < 0.05) reduced severity score in the LC-Plasma group when study sites were separately analyzed. Overall, our findings suggest that LC-Plasma supplementation reduces the cumulative days with DF-like symptoms, and the severity of the symptoms. Daily oral intake of LC-Plasma, hence, is shown to mitigate the DF-like symptoms.

scholarly journals The Effects of Dietary Supplementation of Lactococcus lactis Strain Plasma on Skin Microbiome and Skin Conditions in Healthy Subjects—A Randomized, Double-Blind, Placebo-Controlled Trial

2021 ◽  
Vol 9 (3) ◽  
pp. 563
Author(s):  
Ryohei Tsuji ◽  
Kamiyu Yazawa ◽  
Takeshi Kokubo ◽  
Yuumi Nakamura ◽  
Osamu Kanauchi
Keyword(s):  
Gene Expression ◽  
Lactococcus Lactis ◽  
Healthy Subjects ◽  
Controlled Trial ◽  
Dietary Supplementation ◽  
Skin Microbiome ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Lactis Strain ◽  
Skin Conditions

(1) Background: Lactococcus lactis strain Plasma (LC-Plasma) is a unique strain which directly activates plasmacytoid dendritic cells, resulting in the prevention against broad spectrum of viral infection. Additionally, we found that LC-Plasma intake stimulated skin immunity and prevents Staphylococcus aureus epicutaneous infection. The aim of this study was to investigate the effect of LC-Plasma dietary supplementation on skin microbiome, gene expression in the skin, and skin conditions in healthy subjects. (2) Method: A randomized, double-blind, placebo-controlled, parallel-group trial was conducted. Seventy healthy volunteers were enrolled and assigned into two groups receiving either placebo or LC-Plasma capsules (approximately 1 × 1011 cells/day) for 8 weeks. The skin microbiome was analyzed by NGS and qPCR. Gene expression was analyzed by qPCR and skin conditions were diagnosed by dermatologists before and after intervention. (3) Result: LC-Plasma supplementation prevented the decrease of Staphylococcus epidermidis and Staphylococcus pasteuri and overgrowth of Propionibacterium acnes. In addition, LC-Plasma supplementation suggested to increase the expression of antimicrobial peptide genes but not tight junction genes. Furthermore, the clinical scores of skin conditions were ameliorated by LC-Plasma supplementation. (4) Conclusions: Our findings provided the insights that the dietary supplementation of LC-Plasma might have stabilizing effects on seasonal change of skin microbiome and skin conditions in healthy subjects.

An engineered Lactococcus lactis strain exerts significant immune responses through efficient expression and delivery of Helicobacter pylori Lpp20 antigen

2016 ◽  
Vol 38 (12) ◽  
pp. 2169-2175 ◽  
Author(s):  
Rongguang Zhang ◽  
Xiaoyan Peng ◽  
Guangcai Duan ◽  
Qingfeng Shi ◽  
Shuaiyin Chen ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Immune Responses ◽  
Lactococcus Lactis ◽  
Efficient Expression ◽  
Lactis Strain

scholarly journals Complete Genome Sequence of Lactococcus lactis subsp. lactis Strain 14B4, Which Inhibits the Growth of Salmonella enterica Serotype Poona In Vitro

2018 ◽  
Vol 7 (19) ◽  
Author(s):  
Thao D. Tran ◽  
Steven Huynh ◽  
Craig T. Parker ◽  
Ruyang Han ◽  
Robert Hnasko ◽  
...  
Keyword(s):  
Lactococcus Lactis ◽  
Genome Sequence ◽  
Complete Genome Sequence ◽  
Salmonella Enterica ◽  
Complete Genome ◽  
Northern California ◽  
Content Type ◽  
Lactococcus Lactis Subsp ◽  
Lactis Strain

We present here the complete genome sequence of Lactococcus lactis strain 14B4, isolated from almond drupes in northern California. This strain was observed to inhibit the growth of Salmonella enterica serotype Poona strain RM3363 in vitro.

scholarly journals Lactococcus lactis Strain Plasma Improves Subjective Physical State and Presenteeism: A Randomized, Open-Label Crossover Study among Healthy Office Workers

2020 ◽  
Vol 25 (2) ◽  
pp. 140-145
Author(s):  
Takeshi Kokubo ◽  
Shimpei Wakai ◽  
Daisuke Fujiwara ◽  
Osamu Kanauchi ◽  
Kenta Jounai ◽  
...  
Keyword(s):  
Crossover Study ◽  
Lactococcus Lactis ◽  
Physical State ◽  
Office Workers ◽  
Open Label ◽  
Lactis Strain

Long-term administration of pDC-Stimulative Lactococcus lactis strain decelerates senescence and prolongs the lifespan of mice

2018 ◽  
Vol 58 ◽  
pp. 166-172 ◽  
Author(s):  
Tetsu Sugimura ◽  
Kenta Jounai ◽  
Konomi Ohshio ◽  
Hiroaki Suzuki ◽  
Takayoshi Kirisako ◽  
...  
Keyword(s):  
Lactococcus Lactis ◽  
Term Administration ◽  
Lactis Strain

scholarly journals Characterization of a Lactococcus lactis Strain That Secretes a Major Epitope of Bovine Beta-Lactoglobulin and Evaluation of Its Immunogenicity in Mice

2003 ◽  
Vol 69 (11) ◽  
pp. 6620-6627 ◽  
Author(s):  
Jean-Marc Chatel ◽  
Sebastien Nouaille ◽  
Karine Adel-Patient ◽  
Yves Le Loir ◽  
Herman Boe ◽  
...  
Keyword(s):  
Immune Response ◽  
Fusion Protein ◽  
Lactococcus Lactis ◽  
Immunoglobulin E ◽  
Specific Ige ◽  
Specific Immune Response ◽  
Lactis Strain ◽  
Beta Lactoglobulin ◽  
Β Lactoglobulin

ABSTRACT Bovine β-lactoglobulin (Blg) is one of the major cow's milk allergens. Peptide 41-60 of Blg (Blg41-60) was described as a murine T-cell determinant and a murine, rat, and human immunoglobulin E (IgE) epitope. The aim of this study was the expression of Blg41-60 as a fusion protein in the food-grade bacterium Lactococcus lactis and the characterization of its immunogenicity in mice. We constructed a recombinant strain of L. lactis capable of inducible production and secretion of Blg41-60::Nuc, a fusion protein between Blg41-60 and the mature part of the staphylococcal nuclease (Nuc). The highest production yield of Blg41-60::Nuc (32.5 mg/liter) was reached 4 h after induction. At this time, up to 75% of Blg41-60::Nuc was secreted. When monoclonal antibodies specific for Blg41-60 were used, purified Blg41-60::Nuc and synthetic Blg41-60 exhibited very similar immunoreactivities. Subcutaneous coadministration of purified Blg41-60::Nuc and killed nonrecombinant L. lactis resulted in the induction of specific anti-Blg41-60 IgG2a and IgG1. The IgG1/IgG2a ratio and the lack of specific IgE suggest a Th1-type immune response, i.e., a nonallergic response. Similar administrations of the killed Blg41-60::Nuc-producing L. lactis strain did not elicit a specific immune response, whereas a transitory mucosal IgA-specific immune response was induced in mice after oral administration of the live Blg41-60::Nuc-producing L. lactis strain.

scholarly journals Circulating Ionized Magnesium as a Measure of Supplement Bioavailability: Results from a Pilot Study for Randomized Clinical Trial

Nutrients ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1245 ◽  
Author(s):  
Jiada Zhan ◽  
Taylor C. Wallace ◽  
Sarah J. Butts ◽  
Sisi Cao ◽  
Velarie Ansu ◽  
...  
Keyword(s):  
Pilot Study ◽  
Whole Blood ◽  
Area Under The Curve ◽  
Oral Intake ◽  
Magnesium Content ◽  
Magnesium Concentration ◽  
Rank Test ◽  
Ionized Magnesium ◽  
Signed Rank Test ◽  
Total Magnesium

Oral supplementation may improve the dietary intake of magnesium, which has been identified as a shortfall nutrient. We conducted a pilot study to evaluate appropriate methods for assessing responses to the ingestion of oral magnesium supplements, including ionized magnesium in whole blood (iMg2+) concentration, serum total magnesium concentration, and total urinary magnesium content. In a single-blinded crossover study, 17 healthy adults were randomly assigned to consume 300 mg of magnesium from MgCl2 (ReMag®, a picosized magnesium formulation) or placebo, while having a low-magnesium breakfast. Blood and urine samples were obtained for the measurement of iMg2+, serum total magnesium, and total urine magnesium, during 24 h following the magnesium supplement or placebo dosing. Bioavailability was assessed using area-under-the-curve (AUC) as well as maximum (Cmax) and time-to-maximum (Tmax) concentration. Depending on normality, data were expressed as the mean ± standard deviation or median (range), and differences between responses to MgCl2 or placebo were measured using the paired t-test or Wilcoxon signed-rank test. Following MgCl2 administration versus placebo administration, we observed significantly greater increases in iMg2+ concentrations (AUC = 1.51 ± 0.96 vs. 0.84 ± 0.82 mg/dL•24h; Cmax = 1.38 ± 0.13 vs. 1.32 ± 0.07 mg/dL, respectively; both p < 0.05) but not in serum total magnesium (AUC = 27.00 [0, 172.93] vs. 14.55 [0, 91.18] mg/dL•24h; Cmax = 2.38 [1.97, 4.01] vs. 2.24 [1.98, 4.31] mg/dL) or in urinary magnesium (AUC = 201.74 ± 161.63 vs. 139.30 ± 92.84 mg•24h; Cmax = 26.12 [12.91, 88.63] vs. 24.38 [13.51, 81.51] mg/dL; p > 0.05). Whole blood iMg2+ may be a more sensitive measure of acute oral intake of magnesium compared to serum and urinary magnesium and may be preferred for assessing supplement bioavailability.

scholarly journals Draft Genome Sequence of Lactococcus lactis subsp. lactis Strain YF11

2013 ◽  
Vol 1 (4) ◽  
Author(s):  
Y. Du ◽  
L. Song ◽  
W. Feng ◽  
G. Pei ◽  
P. Zheng ◽  
...  
Keyword(s):  
Lactococcus Lactis ◽  
Genome Sequence ◽  
Draft Genome ◽  
Draft Genome Sequence ◽  
Lactococcus Lactis Subsp ◽  
Lactis Strain

scholarly journals An engineered food-grade Lactococcus lactis strain for production and delivery of heat-labile enterotoxin B subunit to mucosal sites

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Nan Sun ◽  
Rongguang Zhang ◽  
Guangcai Duan ◽  
Xiaoyan Peng ◽  
Chen Wang ◽  
...  
Keyword(s):  
Lactococcus Lactis ◽  
Food Grade ◽  
B Subunit ◽  
Heat Labile ◽  
Lactis Strain ◽  
Enterotoxin B
Sign in / Sign up

Export Citation Format

Share Document